United Therapeutics CEO Martine Rothblatt Executes 10b5-1 Option Exercise and Sale

Executive Summary

On September 2, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed a pre-arranged Rule 10b5-1 trading transaction involving the exercise of 9,500 stock options at an exercise price of $135.42 and the subsequent open-market sale of all 9,500 shares across multiple tranches at weighted average prices ranging between $477.70 and $510.05 per share, yielding total gross proceeds of approximately $4.69 million.

Transaction Breakdown

• Derivative Exercise: Exercised 9,500 options expiring March 15, 2027 at a strike price of $135.42 per share (total exercise cost of ~$1,286,490).
• Open-Market Sales: Disposed of 9,500 shares of Common Stock in 23 separate tranches at an aggregate average price of ~$493.46 per share, realizing approximately $4,687,840.46 in gross sale proceeds.
• Plan Context: These transactions were executed pursuant to a Rule 10b5-1 trading plan established on November 7, 2025.

Post-Transaction Holdings

Following the transactions, Dr. Rothblatt continues to hold substantial equity in United Therapeutics:

• Trust Holdings (Transacting Entity): 324,443 shares
• Direct Holdings: 40,513 shares
• Other Family Trust / Indirect Holdings: Over 303,000 additional shares
• Remaining Option Position in Trust: 8,910 options expiring March 15, 2027